Carebastine (BioDeep_00000696434)

   


代谢物信息卡片


Carebastine

化学式: C32H37NO4 (499.2722)
中文名称: 卡瑞斯汀
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CC(C)(C1=CC=C(C=C1)C(=O)CCCN2CCC(CC2)OC(C3=CC=CC=C3)C4=CC=CC=C4)C(=O)O
InChI: InChI=1S/C32H37NO4/c1-32(2,31(35)36)27-17-15-24(16-18-27)29(34)14-9-21-33-22-19-28(20-23-33)37-30(25-10-5-3-6-11-25)26-12-7-4-8-13-26/h3-8,10-13,15-18,28,30H,9,14,19-23H2,1-2H3,(H,35,36)

描述信息

D018377 - Neurotransmitter Agents > D018494 - Histamine Agents > D006633 - Histamine Antagonists
C308 - Immunotherapeutic Agent > C29578 - Histamine-1 Receptor Antagonist
D019141 - Respiratory System Agents > D018927 - Anti-Asthmatic Agents
Carebastine is the active metabolite of Ebastine. Carebastine is a histamine H1 receptor antagonist. Carebastine inhibits VEGF-induced HUVEC and HPAEC proliferation, migration and angiogenesis in a dose-dependent manner[1]. Carebastine suppresses the expression of macrophage migration inhibitory factor[2].

同义名列表

1 个代谢物同义名

Carebastine



数据库引用编号

5 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。

亚细胞结构定位 关联基因列表


文献列表

  • Margaret Phiri, Duo Li, Tengfei Li, Shunli Ji, Tang Ling, Xianjing Li, Huaye Gao, Li Ding, Chang Shu. Method development and validation for simultaneous determination of ebastine and its active metabolite carebastine in human plasma by liquid chromatography-tandem mass spectrometry and its application to a clinical pharmacokinetic study in healthy Chinese volunteers. Biomedical chromatography : BMC. 2020 Oct; 34(10):e4904. doi: 10.1002/bmc.4904. [PMID: 32449558]
  • J Saito, N Yakuwa, N Sandaiji, S Yagishita, H Kawasaki, T Suzuki, K Ozawa, S Kamura, A Yamatani, S Wada, H Sago, A Murashima. Ebastine during pregnancy and lactation in a patient with chronic urticaria: ebastine and carebastine levels in maternal serum, cord blood, breast milk and the infant's serum. Journal of the European Academy of Dermatology and Venereology : JEADV. 2020 Sep; 34(9):e496-e497. doi: 10.1111/jdv.16415. [PMID: 32249465]
  • Myung-Jae Lee, Heon-Woo Lee, Jong-Min Kang, Ji-Hyung Seo, Seong-Kun Tak, Wangseob Shim, Sung-Vin Yim, Seung Jae Hong, Kyung-Tae Lee. Application of a rapid and selective method for the simultaneous determination of carebastine and pseudoephedrine in human plasma by liquid chromatography-electrospray mass spectrometry for bioequivalence study in Korean subjects. Biomedical chromatography : BMC. 2010 Oct; 24(10):1031-7. doi: 10.1002/bmc.1392. [PMID: 20099369]
  • Ji-Hong Shon, Chang-Woo Yeo, Kwang-Hyeon Liu, Sang-Seop Lee, In-Jun Cha, Jae-Gook Shin. Itraconazole and rifampin alter significantly the disposition and antihistamine effect of ebastine and its metabolites in healthy participants. Journal of clinical pharmacology. 2010 Feb; 50(2):195-204. doi: 10.1177/0091270009348974. [PMID: 19841159]
  • Sayaka Kato, Yukio Kato, Tadakatsu Nakamura, Tomoko Sugiura, Yoshiyuki Kubo, Yoshiharu Deguchi, Akira Tsuji. Genetic deficiency of carnitine/organic cation transporter 2 (slc22a5) is associated with altered tissue distribution of its substrate pyrilamine in mice. Biopharmaceutics & drug disposition. 2009 Dec; 30(9):495-507. doi: 10.1002/bdd.681. [PMID: 19821448]
  • Robert J Noveck, Richard A Preston, Suzanne K Swan. Pharmacokinetics and safety of ebastine in healthy subjects and patients with renal impairment. Clinical pharmacokinetics. 2007; 46(6):525-34. doi: 10.2165/00003088-200746060-00006. [PMID: 17518511]
  • Guillermo Gervasini, Sonia Vizcaino, Juan Antonio Carrillo, Maria Jesus Caballero, Julio Benitez. The effect of CYP2J2, CYP3A4, CYP3A5 and the MDR1 polymorphisms and gender on the urinary excretion of the metabolites of the H-receptor antihistamine ebastine: a pilot study. British journal of clinical pharmacology. 2006 Aug; 62(2):177-86. doi: 10.1111/j.1365-2125.2006.02578.x. [PMID: 16842392]
  • Hampel Frank, Michael Gillen, Shashank S Rohatagi, Janet Lim, George George. A double-blind, placebo-controlled study of the efficacy and safety of ebastine 20 mg once daily given with and without food in the treatment of seasonal allergic rhinitis. Journal of clinical pharmacology. 2002 Oct; 42(10):1097-104. doi: 10.1177/009127002401382696. [PMID: 12362923]
  • M Matsuda, Y Mizuki, Y Terauchi. Simultaneous determination of the histamine H1-receptor antagonist ebastine and its two metabolites, carebastine and hydroxyebastine, in human plasma using high-performance liquid chromatography. Journal of chromatography. B, Biomedical sciences and applications. 2001 Jun; 757(1):173-9. doi: 10.1016/s0378-4347(00)00494-1. [PMID: 11419742]
  • S Rohatagi, M Gillen, M Aubeneau, C Jan, B Pandit, B K Jensen, G Rhodes. Effect of age and gender on the pharmacokinetics of ebastine after single and repeated dosing in healthy subjects. International journal of clinical pharmacology and therapeutics. 2001 Mar; 39(3):126-34. doi: 10.5414/cpp39126. [PMID: 11396753]
  • I Tamai, Y Kido, J Yamashita, Y Sai, A Tsuji. Blood-brain barrier transport of H1-antagonist ebastine and its metabolite carebastine. Journal of drug targeting. 2000; 8(6):383-93. doi: 10.3109/10611860008997914. [PMID: 11328664]
  • H Ohtani, H Sato, T Iga, H Kotaki, Y Sawada. Pharmacokinetic-pharmacodynamic analysis of the arrhythmogenic potency of a novel antiallergic agent, ebastine, in rats. Biopharmaceutics & drug disposition. 1999 Mar; 20(2):101-6. doi: 10.1002/(sici)1099-081x(199903)20:2<101::aid-bdd160>3.0.co;2-l. [PMID: 10206325]
  • H Fischer, R Gottschlich, A Seelig. Blood-brain barrier permeation: molecular parameters governing passive diffusion. The Journal of membrane biology. 1998 Oct; 165(3):201-11. doi: 10.1007/s002329900434. [PMID: 9767674]
  • J M Jansat, C F Lastra, E L Mariño. Comparative study of different weighting methods in non-linear regression analysis: implications in the parametrization of carebastine after intravenous administration in healthy volunteers. International journal of clinical pharmacology and therapeutics. 1998 Jun; 36(6):340-4. doi: NULL. [PMID: 9660043]
  • A Pagliara, B Testa, P A Carrupt, P Jolliet, C Morin, D Morin, S Urien, J P Tillement, J P Rihoux. Molecular properties and pharmacokinetic behavior of cetirizine, a zwitterionic H1-receptor antagonist. Journal of medicinal chemistry. 1998 Mar; 41(6):853-63. doi: 10.1021/jm9704311. [PMID: 9526560]
  • T Fujii, S Matsumoto, H Amejima, T Hatoyama, M Nakao, A Kagemoto, K Tanaka, H Miyazaki. Absorption, distribution, metabolism and excretion of [14C]ebastine after a single administration in rats. Arzneimittel-Forschung. 1994 Apr; 44(4):527-38. doi: NULL. [PMID: 7912071]
  • M Matsuda, M Sakashita, Y Mizuki, T Yamaguchi, T Fujii, Y Sekine. Comparative pharmacokinetics of the histamine H1-receptor antagonist ebastine and its active metabolite carebastine in rats, guinea pigs, dogs and monkeys. Arzneimittel-Forschung. 1994 Jan; 44(1):55-9. doi: NULL. [PMID: 7907872]
  • T Yamaguchi, T Hashizume, M Matsuda, M Sakashita, T Fujii, Y Sekine, M Nakashima, T Uematsu. Pharmacokinetics of the H1-receptor antagonist ebastine and its active metabolite carebastine in healthy subjects. Arzneimittel-Forschung. 1994 Jan; 44(1):59-64. doi: NULL. [PMID: 7907873]
  • J Van Rooij, H C Schoemaker, R Bruno, J F Reinhoudt, D D Breimer, A F Cohen. Cimetidine does not influence the metabolism of the H1-receptor antagonist ebastine to its active metabolite carebastine. British journal of clinical pharmacology. 1993 Jun; 35(6):661-3. doi: 10.1111/j.1365-2125.1993.tb04199.x. [PMID: 8101096]
  • M J Mattila, K Aranko, T Kuitunen. Diazepam effects on the performance of healthy subjects are not enhanced by treatment with the antihistamine ebastine. British journal of clinical pharmacology. 1993 Mar; 35(3):272-7. doi: 10.1111/j.1365-2125.1993.tb05694.x. [PMID: 8097102]
  • J Vincent, R Liminana, P A Meredith, J L Reid. The pharmacokinetics, antihistamine and concentration-effect relationship of ebastine in healthy subjects. British journal of clinical pharmacology. 1988 Nov; 26(5):497-502. doi: 10.1111/j.1365-2125.1988.tb05288.x. [PMID: 2905150]